Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 469.73M P/E 2.85 EPS this Y 38.40% Ern Qtrly Grth -
Income -125.97M Forward P/E -5.50 EPS next Y -7.50% 50D Avg Chg -11.00%
Sales 50.46M PEG -0.79 EPS past 5Y - 200D Avg Chg -12.00%
Dividend N/A Price/Book 0.99 EPS next 5Y 11.00% 52W High Chg -32.00%
Recommedations 2.00 Quick Ratio 6.61 Shares Outstanding 70.70M 52W Low Chg 78.00%
Insider Own 4.48% ROA -16.15% Shares Float 41.96M Beta 1.15
Inst Own 96.09% ROE -27.64% Shares Shorted/Prior 5.02M/5.03M Price 7.32
Gross Margin -158.24% Profit Margin -249.63% Avg. Volume 599,495 Target Price 14.46
Oper. Margin -383.87% Earnings Date - Volume 406,252 Change -1.74%
About Zymeworks Inc.

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

Zymeworks Inc. News
05/05/24 Zymeworks Inc. (NASDAQ:ZYME) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
05/02/24 Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results
04/30/24 Zymeworks Announces Participation in Upcoming Investor Conferences
04/28/24 We Think Zymeworks (NASDAQ:ZYME) Can Afford To Drive Business Growth
04/11/24 Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
04/08/24 Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting
03/28/24 Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors
03/06/24 Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results
03/05/24 Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting
02/14/24 Zymeworks To Host Fourth Quarter and Full Year 2023 Results Conference Call
02/08/24 Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors
01/04/24 Zymeworks Outlines Strategic Priorities and Outlook for 2024 and 2025
01/04/24 Zymeworks Announces Additional Leadership Appointments
12/26/23 Zymeworks Announces $50 Million Private Placement to EcoR1 Capital
12/15/23 Zymeworks Added to Nasdaq Biotechnology Index
11/30/23 Zymeworks Announces Participation in Upcoming Investor Conference
11/07/23 Zymeworks Provides Corporate Update and Reports Third Quarter 2023 Financial Results
10/17/23 Zymeworks To Host Third Quarter 2023 Results Conference Call
10/16/23 Zymeworks Announces New Director Nominee
08/10/23 Zymeworks Provides Corporate Update and Reports Second Quarter 2023 Financial Results
ZYME Chatroom

User Image maplelakeduckslayer Posted - 2 days ago

$ZYME

User Image FetchDog Posted - 5 days ago

$ZYME Bought a new entry position today ($8.88). I've been patiently waiting for this to show some type of a bottom. Seems to me like we are near a bottom before another trend up. Analysts do not see a lot of upside here, so the stock is drifting after the recent ER. However, I'm betting there will be significant stock price apreciation in 24-H2. Plenty of catalysts, plus the all the signs (as pointed out by @maplelakeduckslayer) that they plan to pump this to raise capital at a higher price. Biotech ups and downs are all about catalysts and pumps. There is almost always a nice pump before raising capital. Beware of bad CPI inflation data on May 15 - could send biotech down.

User Image maplelakeduckslayer Posted - 1 week ago

$ZYME looks like I need to buy a new chair for myself 🀣

User Image Scientwist Posted - 1 week ago

$ZYME Zymeworks Inc. (ZYME) disappoints in Q1 with revenue and earnings missing forecasts. Analysts adjust 2024 revenue predictions to $82.2m, eyeing a 63% year-over-year growth, but widen loss expectations to $1.37/share. Despite downgrades, consensus price target remains at $13.72. Revenue growth outlook beats industry average, signaling potential long-term upside. #ZYME #EarningsMiss #StockMarket #Neutral

User Image Scientwist Posted - 1 week ago

$ZYME πŸš€πŸ’₯ **#Zymeworks shifts gears with a strategic pivot, focusing on long-term growth despite Q1 revenue shifts. With a robust $420.5M cash reserve to propel operations into H2 2027, and the promising pipeline, including zanidatamab, Zymeworks is setting the stage for groundbreaking advancements. 🌟 The future looks bright as they navigate the biotech frontier. #Biotech #Investing πŸ“ˆπŸ”¬βœ¨

User Image maplelakeduckslayer Posted - 1 week ago

$ZYME they filed a shelf this is super bullish they know the demand cycle is about to start up with all the upcoming prs and can take advantage raising additional capital on the pump...this is gonna be awesome

User Image DonCorleone77 Posted - 1 week ago

$ZYME Zymeworks reports Q1 EPS (42c), consensus (29c) Reports Q1 revenue $10.03M, consensus $17.43M. Reports $420.5M in cash resources as of March 31, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into second half of 2027. The company said, "We are very pleased to have presented five poster presentations at AACR, which showcase Zymeworks' ability to apply key insights from our proprietary technology and in-house expertise to optimize our product development candidates for targets of significant interest. As we prepare to enter multiple Phase 1 trials in the coming 24 months, our commitment to advancing innovative solutions remains evident, with more preclinical data for our early-stage pipeline to be presented throughout 2024. Consistent with our previous disclosures, our anticipated cash runway remains on track to support the development of our 5 by 5 product pipeline into the second half of 2027. While we approach milestones that may result in further extension of this runway."

User Image Stock_Titan Posted - 1 week ago

$ZYME Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results https://www.stocktitan.net/news/ZYME/zymeworks-provides-corporate-update-and-reports-first-quarter-2024-aa5dif5wx1hk.html

User Image maplelakeduckslayer Posted - 1 week ago

$ZYME just a taste shorts...imagine news with the whole free float short🀣

User Image maplelakeduckslayer Posted - 1 week ago

$ZYME

User Image Nickhzap Posted - 1 week ago

$ZYME HERIZON GEA data could be released at any moment. Primary endpoint of OS was estimated around June 2024. And there has been $100 million worth on institutional inflows this year and tutes comprise 93% of shareholders πŸ‘€πŸ‘€πŸ‘€πŸ‘€

User Image Stock_Titan Posted - 04/30/24

$ZYME Zymeworks Announces Participation in Upcoming Investor Conferences https://www.stocktitan.net/news/ZYME/zymeworks-announces-participation-in-upcoming-investor-4t21t3cpglmy.html

User Image ABACABB Posted - 04/25/24

$ZYME showing the world what relentless bearishness looks like. Never ending drop to nothingness.

User Image stock_smat Posted - 04/25/24

$ZYME It doesn't make sense that Zyme is red everyday for last 2 months without any news ... any explaination ???

User Image maplelakeduckslayer Posted - 04/20/24

$ZYME This really doesnt want to be trading under $10 the lack of volume and repeated indecision candles/attempts at reversal show that the big red candle on CFO getting fired and breaking below $10 was a completely fake move. There was nothing negative associated with that event the company just wanted a better candidate. This gave a higher volume reversal indication friday with a bullish engulfing and a close back over the 200 ma. The weekly also reclaimed and closed back over the 50 ma. The monthly has not ceased looking bullish asf. The overall fear in the macroenvironment has caused an illogical move to the downside. This may be ready for reversal here ahead of several catalyst coming by June.

User Image Aigner_Andreas Posted - 04/20/24

TD BUY $ZYME at 8.85, Supp 8.67 Resis 9.66 R11 HiLo 40% T1Y 17 buy 2.0 DIV N/A #Zymeworks #stocks #trading #finance #market

User Image stock_smat Posted - 04/19/24

$ZYME What just happened ?? AH +$0.66 !!

User Image maplelakeduckslayer Posted - 04/18/24

$ZYME This is juiced to the gills... almost 10 days to cover with 85-90% of the float held by tutes lmfaooo. Tic Toc, as someone who shorts like 70% of my trades...I dunno how you possibly think this is a good risk reward trade with it sitting at asset value, with this share structure and several known prs due by june. This is absolutely beautiful if they can start rolling out some prs This will be a face ripppa

User Image ScoobieDoo Posted - 04/18/24

$ZYME so the big question is what other bad news hasn't been released that might be related to CFO exit. Luckily volume has been light for this recent drop.

User Image Fast_Eddie_Felson Posted - 04/17/24

$ZYME added 8.88 for dragon luck

User Image ScoobieDoo Posted - 04/15/24

$ZYME https://www.jazzpharma.com/science/pipeline/ Think they believe in Zani?

User Image G101SPM Posted - 04/15/24

#SHOWTIME Stifel Virtual Targeted Oncology (April 16) Scheduled to appear: $IDYA, $ZYME Moody's Corporation Annual General Meeting (April 16) Scheduled to appear: $MCO First Moline Finl Corp Com Annual General Meeting (April 16) Scheduled to appear: $USB Spotify Technology SA Annual General Meeting (April 16) Scheduled to appear: $SPOT

User Image maplelakeduckslayer Posted - 1 month ago

$ZYME

User Image lllIIIII Posted - 1 month ago

@Samalex $ZYME is a speculative play but not as speculative as the other tickers mentioned lol

User Image maplelakeduckslayer Posted - 1 month ago

$ZYME Textbook morning star reversal pattern see if they play it

User Image Samalex Posted - 1 month ago

My speculative plays are $NYCB $RGTI $SOUN $ZYME $RIVN. If 3 out 5 turn out to be good picks, I will be very happy 🍺🍺

User Image Stock_Titan Posted - 1 month ago

$ZYME Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024 https://www.stocktitan.net/news/ZYME/zymeworks-to-report-first-quarter-2024-financial-results-and-host-rluo2qbcpzqw.html

User Image maplelakeduckslayer Posted - 1 month ago

$ZYME

User Image Stock_Titan Posted - 1 month ago

$ZYME Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting https://www.stocktitan.net/news/ZYME/zymeworks-presents-new-data-from-multiple-preclinical-development-vg8cdq3f3pde.html

User Image maplelakeduckslayer Posted - 1 month ago

$ZYME nothing bad happened with the CFO leaving

Analyst Ratings
HC Wainwright & Co. Neutral May 7, 24
Citigroup Buy May 3, 24
Wells Fargo Overweight May 3, 24
Wells Fargo Overweight Mar 12, 24
HC Wainwright & Co. Neutral Mar 11, 24
HC Wainwright & Co. Neutral Aug 15, 23
HC Wainwright & Co. Neutral Jun 6, 23
Citigroup Buy May 18, 23
Stifel Buy May 9, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Galbraith Kenneth Chair & CEO Chair & CEO Jan 05 Sell 10.93 23,904 261,271 23,762 01/08/24
Galbraith Kenneth Chair & CEO Chair & CEO Jan 05 Option 0 47,666 47,666 01/08/24
Astle Christopher SVP & Chief Financia.. SVP & Chief Financial Officer Jan 05 Sell 10.93 5,994 65,514 6,503 01/08/24
Astle Christopher SVP & Chief Financia.. SVP & Chief Financial Officer Jan 05 Option 0 10,500 12,497 01/08/24
Moore Paul Andrew Chief Scientific Off.. Chief Scientific Officer Jan 05 Sell 10.93 9,799 107,103 7,367 01/08/24
Moore Paul Andrew Chief Scientific Off.. Chief Scientific Officer Jan 05 Option 0 17,166 17,166 01/08/24
Astle Christopher SVP & Chief Financia.. SVP & Chief Financial Officer Dec 11 Sell 9.13 886 8,089 1,997 12/11/23
Astle Christopher SVP & Chief Financia.. SVP & Chief Financial Officer Dec 11 Option 0 1,550 2,883 12/11/23
EcoR1 Capital, LLC 10% Owner 10% Owner Mar 28 Buy 8 200,000 1,600,000 10,087,473 03/30/23
Klompas Neil A President & COO President & COO Mar 10 Sell 7.83 2,977 23,310 17,032 03/14/23
Klompas Neil A President & COO President & COO Mar 10 Option 0 5,208 20,009 03/14/23
EcoR1 Capital, LLC 10% Owner 10% Owner Jan 19 Buy 9.69 307,500 2,979,675 9,887,473 01/23/23
EcoR1 Capital, LLC 10% Owner 10% Owner Jan 13 Buy 9.87 985,100 9,722,937 9,579,973 01/18/23
EcoR1 Capital, LLC 10% Owner 10% Owner Jan 10 Buy 7.76 1,026,300 7,964,088 8,594,873 01/12/23
Astle Christopher SVP & Chief Financia.. SVP & Chief Financial Officer Dec 12 Option 0 1,550 2,220 12/23/22
Astle Christopher SVP & Chief Financia.. SVP & Chief Financial Officer Dec 12 Sell 6.01 887 5,331 1,333 12/23/22
Josephson Neil Chief Medical Office.. Chief Medical Officer Nov 10 Sell 8.1 2,475 20,048 14,449 12/23/22
Josephson Neil Chief Medical Office.. Chief Medical Officer Nov 10 Option 0 5,885 16,924 12/23/22
Josephson Neil Chief Medical Office.. Chief Medical Officer Nov 10 Option 0 5,885 16,924 11/14/22
Josephson Neil Chief Medical Office.. Chief Medical Officer Nov 10 Sell 8.1 2,475 20,048 14,449 11/14/22
Josephson Neil Chief Medical Office.. Chief Medical Officer Nov 10 Option 0 5,885 16,924 11/14/22
Josephson Neil Chief Medical Office.. Chief Medical Officer Nov 10 Sell 8.1 2,475 20,048 14,449 11/14/22
Redmile Group, LLC 10% Owner 10% Owner Oct 13 Buy 5.0338 30,481 153,435 6,075,918 10/18/22
Klompas Neil A Chief Operating Offi.. Chief Operating Officer Mar 10 Option 0 5,208 16,255 03/11/22
Klompas Neil A Chief Operating Offi.. Chief Operating Officer Mar 10 Sell 6.88 2,979 20,496 13,276 03/11/22
Josephson Neil Chief Medical Office.. Chief Medical Officer Jan 07 Buy 14.28 5,000 71,400 7,119 01/11/22